Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04667572 · ClinicalTrials.gov registry record · Phase 1
Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
A Phase 1 study of Keratoconus and Pellucid Marginal Corneal Degeneration, sponsored by Cornea Associates of Texas.
- Completed
- Registry status
- Phase 1
- Development phase
- 249
- Enrollment target
- 1
- Study location
NCT04667572 is a Phase 1 study of Keratoconus and Pellucid Marginal Corneal Degeneration that has completed, run by Cornea Associates of Texas. The registered enrollment target is 249 participants, below the 1,169-participant average among 21 other Keratoconus trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04667572, a Phase 1 study of Keratoconus and Pellucid Marginal Corneal Degeneration, has completed, sponsored by Cornea Associates of Texas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 249 participants
- Enrollment target
- 1
- Study location
Study Summary
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions
Conditions Studied
Interventions
- COMBINATION_PRODUCT PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Study Locations (1)
Texas
- Cornea Associates of Texas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2024-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04667572
The ClinicalTrials.gov registry entry for NCT04667572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,169-participant average among 21 other Keratoconus trials with a reported enrollment target (79% lower). The listed sponsor is Cornea Associates of Texas, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Keratoconus appearing as the primary indexed condition, and to 1 intervention - of which PXL-330 Platinum device for crosslinking with Peschke riboflavin solution is the first listed.
NCT04667572 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04667572 about?
NCT04667572 is a clinical study titled "Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution". Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions
What is the current status of trial NCT04667572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 249 participants. The study started on 2021-02-01. Estimated completion is 2024-08-21.
What conditions does trial NCT04667572 study?
This clinical trial studies the following conditions: Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Ectasia, Corneal Degeneration.
What interventions are being tested in trial NCT04667572?
The interventions under investigation include: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04667572?
This trial is sponsored by Cornea Associates of Texas, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04667572 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
OCT in Diagnosis of Irregular Corneas
RECRUITING
-
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
RECRUITING · Phase 3
-
Collagen Cross-linking in Keratoconus
RECRUITING · NA
-
Corneal Elastography and Patient Specific Modeling
RECRUITING
-
Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.